A real world analysis of first line treatment of advanced EGFR mutated non-small cell lung cancer: A multi-center, retrospective study

奥西默替尼 医学 肺癌 内科学 中止 肿瘤科 回顾性队列研究 无进展生存期 临床试验 腺癌 癌症 化疗 ROS1型
作者
Chung‐Shien Lee,Iman Zaky Ahmed,Emily Miao,Shirley Chung,Khilna Patel,Nina Kohn,Nagashree Seetharamu
出处
期刊:Journal of Oncology Pharmacy Practice [SAGE Publishing]
卷期号:28 (5): 1140-1151 被引量:9
标识
DOI:10.1177/10781552211020798
摘要

The recently published FLAURA trial demonstrated that osimertinib has remarkable efficacy in front-line setting for non-small cell lung cancer (NSCLC). While this has transformed current practice, there are no effective treatments following progression on osimertinib. The aim of our study was to compare progression-free survival (PFS) and overall survival (OS) between patients initiated on osimertinib to those started on other EGFR TKIs.This was a multicenter, retrospective study conducted at two large academic centers. Adult patients with EGFR-mutated non-small cell lung cancer (NSCLC) who received EGFR therapy between 2014 and 2019 were included. Patients were dichotomized based on front-line TKI (osimertinib vs. other). PFS, OS, and time-to-discontinuation were evaluated.One-hundred seventy-two patients were included in the final analysis. Fifty-two (30.2%) patients received osimertinib and 120 (69.8%) patients received another EGFR TKI. The PFS rates at 6, 12, and 18 months were 86.3%, 79.5%, 69.8% in the osimertinib group and 86.6%, 64.2%, 39.3% in the other EGFR TKI group, respectively (p < 0.0036).Estimated OS at 6, 12, and 18 months was similar for both groups: 94.2%, 94.2%, 80.2% and 95.7%, 93.9%, 84.1%, respectively [Adjusted HR = 0.95 (95% CI, 0.37-2.44; p < 0.9128].Osimertinib demonstrated greater 12 and 18 month PFS compared to other EGFR TKIs. This finding is consistent with results of the FLAURA trial. However, unlike FLAURA, there were no differences in estimated OS between the two groups in our study. Further research to evaluate optimal sequencing strategies in the real world of first, second and third generation TKIs is needed.

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
PDF的下载单位、IP信息已删除 (2025-6-4)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
Xin完成签到,获得积分10
3秒前
Aurora.H完成签到,获得积分10
6秒前
6秒前
FashionBoy应助科研通管家采纳,获得10
7秒前
打打应助科研通管家采纳,获得10
7秒前
Jasper应助科研通管家采纳,获得10
7秒前
Ava应助科研通管家采纳,获得10
7秒前
顾矜应助科研通管家采纳,获得10
7秒前
上官若男应助科研通管家采纳,获得10
7秒前
duckspy发布了新的文献求助10
9秒前
9秒前
9秒前
xiaowan完成签到,获得积分10
10秒前
Terry完成签到,获得积分10
11秒前
张张张哈哈哈完成签到,获得积分10
11秒前
Research完成签到 ,获得积分10
11秒前
称心采枫完成签到 ,获得积分0
12秒前
12秒前
新新新新新发顶刊完成签到 ,获得积分10
13秒前
L3完成签到,获得积分10
14秒前
我是科研小能手完成签到,获得积分10
14秒前
风中的小丸子完成签到,获得积分10
15秒前
15秒前
时尚俊驰发布了新的文献求助10
16秒前
16秒前
16秒前
Grin完成签到,获得积分10
17秒前
周周完成签到,获得积分20
17秒前
18秒前
liufan完成签到 ,获得积分10
20秒前
guitarist完成签到 ,获得积分10
20秒前
饮汽水完成签到,获得积分10
20秒前
20秒前
yoyo20012623完成签到,获得积分10
21秒前
伦语发布了新的文献求助10
21秒前
韵苑完成签到,获得积分10
23秒前
烟花应助人生如梦采纳,获得10
23秒前
饮汽水发布了新的文献求助10
24秒前
先一完成签到 ,获得积分10
24秒前
25秒前
高分求助中
【提示信息,请勿应助】关于scihub 10000
Les Mantodea de Guyane: Insecta, Polyneoptera [The Mantids of French Guiana] 3000
徐淮辽南地区新元古代叠层石及生物地层 3000
The Mother of All Tableaux: Order, Equivalence, and Geometry in the Large-scale Structure of Optimality Theory 3000
Handbook of Industrial Diamonds.Vol2 1100
Global Eyelash Assessment scale (GEA) 1000
Picture Books with Same-sex Parented Families: Unintentional Censorship 550
热门求助领域 (近24小时)
化学 材料科学 医学 生物 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 遗传学 基因 物理化学 催化作用 冶金 细胞生物学 免疫学
热门帖子
关注 科研通微信公众号,转发送积分 4038201
求助须知:如何正确求助?哪些是违规求助? 3575940
关于积分的说明 11373987
捐赠科研通 3305747
什么是DOI,文献DOI怎么找? 1819274
邀请新用户注册赠送积分活动 892662
科研通“疑难数据库(出版商)”最低求助积分说明 815022